Evonik sells Hanau pharma assets to ProChem in strategic portfolio shift
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
Subscribe To Our Newsletter & Stay Updated